Similar articles

• Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

  Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Bueno-de-Mesquita JM, et al. Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Lancet Oncol. 2007. PMID: 18042430
• Translation, please.

  Bleiweiss IJ, Raptis G. Bleiweiss IJ, et al. Lancet Oncol. 2007 Dec;8(12):1044-1045. doi: 10.1016/S1470-2045(07)70349-2. Lancet Oncol. 2007. PMID: 18054869 No abstract available.
• Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.

  Cosler LE, Lyman GH. Cosler LE, et al. Cancer Invest. 2009 Dec;27(10):953-9. doi: 10.3109/07357900903275217. Cancer Invest. 2009. PMID: 19909009 No abstract available.
• Integrating breast cancer genetics into clinical practice.

  Mukherjee A, Rakha EA. Mukherjee A, et al. Womens Health (Lond). 2012 Jan;8(1):99-112. doi: 10.2217/whe.11.81. Womens Health (Lond). 2012. PMID: 22171779 Review.
• Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX^® Breast Recurrence Score Assay.

  Curtit E, Mansi L, Maisonnette-Escot Y, Sautière JL, Pivot X. Curtit E, et al. Eur J Surg Oncol. 2017 May;43(5):921-930. doi: 10.1016/j.ejso.2016.11.016. Epub 2016 Dec 14. Eur J Surg Oncol. 2017. PMID: 28087099 Review.